CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma

Vishwa Jeet Amatya, Yukio Takeshima, Keisuke Aoe, Nobukazu Fujimoto, Toshihiro Okamoto, Taketo Yamada, Takumi Kishimoto, Chikao Morimoto, Kouki Inai

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

CD9 is involved in cell growth, adhesion and motility and its expression is reported to be of prognostic significance in various types of human malignancies. We found increased cell migration in the mesothelioma cell lines MSTO-211H and TUM1 following in vitro shRNA-mediated knockdown of CD9 expression. We investigated CD9 expression in 112 malignant pleural mesotheliomas. CD9 expression was observed in 62 of 71 epithelioid, 13 of 20 biphasic and only 1 of 21 sarcomatoid mesotheliomas. Among the epithelioid mesotheliomas (EMs), CD9 expression was observed in all of the 33 cases with a differentiated type (EM-D) and in 29 of the 38 cases with a less-differentiated type (EM-LD). Patients with CD9 expression showed higher 1- and 2-year survival rates (63 and 25%) compared to the patients without CD9 expression (39 and 11%). Univariate analysis revealed that patients with CD9 expression demonstrated a more favorable survival (P=0.0025) along with other clinicopathological factors, including age younger than 60 years, IMIG stage I-II, epithelioid histology, EM-D and patients who underwent extrapleural pneumonectomy or received chemotherapy. Multivariate analysis identified CD9 expression as an independent prognostic factor with a hazard ratio (HR) of 1.99 in the analysis of all mesotheliomas (P=0.0261) and an HR of 2.60 in the analysis of EMs (P=0.0376). CD9 expression is an independent favorable prognostic marker of malignant mesothelioma.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalOncology Reports
Volume29
Issue number1
DOIs
Publication statusPublished - 2013 Jan

Fingerprint

Mesothelioma
Cell Movement
Pneumonectomy
Malignant Mesothelioma
Age Factors
Cell Adhesion
Small Interfering RNA
Histology
Multivariate Analysis
Survival Rate
Drug Therapy
Cell Line
Survival
Growth

Keywords

  • CD9 immunohistochemistry
  • CD9-shRNA
  • Mesothelioma
  • Migration
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Amatya, V. J., Takeshima, Y., Aoe, K., Fujimoto, N., Okamoto, T., Yamada, T., ... Inai, K. (2013). CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma. Oncology Reports, 29(1), 21-28. https://doi.org/10.3892/or.2012.2116

CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma. / Amatya, Vishwa Jeet; Takeshima, Yukio; Aoe, Keisuke; Fujimoto, Nobukazu; Okamoto, Toshihiro; Yamada, Taketo; Kishimoto, Takumi; Morimoto, Chikao; Inai, Kouki.

In: Oncology Reports, Vol. 29, No. 1, 01.2013, p. 21-28.

Research output: Contribution to journalArticle

Amatya, VJ, Takeshima, Y, Aoe, K, Fujimoto, N, Okamoto, T, Yamada, T, Kishimoto, T, Morimoto, C & Inai, K 2013, 'CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma', Oncology Reports, vol. 29, no. 1, pp. 21-28. https://doi.org/10.3892/or.2012.2116
Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T et al. CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma. Oncology Reports. 2013 Jan;29(1):21-28. https://doi.org/10.3892/or.2012.2116
Amatya, Vishwa Jeet ; Takeshima, Yukio ; Aoe, Keisuke ; Fujimoto, Nobukazu ; Okamoto, Toshihiro ; Yamada, Taketo ; Kishimoto, Takumi ; Morimoto, Chikao ; Inai, Kouki. / CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma. In: Oncology Reports. 2013 ; Vol. 29, No. 1. pp. 21-28.
@article{555998d159bc499ca9baa07f443ae235,
title = "CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma",
abstract = "CD9 is involved in cell growth, adhesion and motility and its expression is reported to be of prognostic significance in various types of human malignancies. We found increased cell migration in the mesothelioma cell lines MSTO-211H and TUM1 following in vitro shRNA-mediated knockdown of CD9 expression. We investigated CD9 expression in 112 malignant pleural mesotheliomas. CD9 expression was observed in 62 of 71 epithelioid, 13 of 20 biphasic and only 1 of 21 sarcomatoid mesotheliomas. Among the epithelioid mesotheliomas (EMs), CD9 expression was observed in all of the 33 cases with a differentiated type (EM-D) and in 29 of the 38 cases with a less-differentiated type (EM-LD). Patients with CD9 expression showed higher 1- and 2-year survival rates (63 and 25{\%}) compared to the patients without CD9 expression (39 and 11{\%}). Univariate analysis revealed that patients with CD9 expression demonstrated a more favorable survival (P=0.0025) along with other clinicopathological factors, including age younger than 60 years, IMIG stage I-II, epithelioid histology, EM-D and patients who underwent extrapleural pneumonectomy or received chemotherapy. Multivariate analysis identified CD9 expression as an independent prognostic factor with a hazard ratio (HR) of 1.99 in the analysis of all mesotheliomas (P=0.0261) and an HR of 2.60 in the analysis of EMs (P=0.0376). CD9 expression is an independent favorable prognostic marker of malignant mesothelioma.",
keywords = "CD9 immunohistochemistry, CD9-shRNA, Mesothelioma, Migration, Survival",
author = "Amatya, {Vishwa Jeet} and Yukio Takeshima and Keisuke Aoe and Nobukazu Fujimoto and Toshihiro Okamoto and Taketo Yamada and Takumi Kishimoto and Chikao Morimoto and Kouki Inai",
year = "2013",
month = "1",
doi = "10.3892/or.2012.2116",
language = "English",
volume = "29",
pages = "21--28",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma

AU - Amatya, Vishwa Jeet

AU - Takeshima, Yukio

AU - Aoe, Keisuke

AU - Fujimoto, Nobukazu

AU - Okamoto, Toshihiro

AU - Yamada, Taketo

AU - Kishimoto, Takumi

AU - Morimoto, Chikao

AU - Inai, Kouki

PY - 2013/1

Y1 - 2013/1

N2 - CD9 is involved in cell growth, adhesion and motility and its expression is reported to be of prognostic significance in various types of human malignancies. We found increased cell migration in the mesothelioma cell lines MSTO-211H and TUM1 following in vitro shRNA-mediated knockdown of CD9 expression. We investigated CD9 expression in 112 malignant pleural mesotheliomas. CD9 expression was observed in 62 of 71 epithelioid, 13 of 20 biphasic and only 1 of 21 sarcomatoid mesotheliomas. Among the epithelioid mesotheliomas (EMs), CD9 expression was observed in all of the 33 cases with a differentiated type (EM-D) and in 29 of the 38 cases with a less-differentiated type (EM-LD). Patients with CD9 expression showed higher 1- and 2-year survival rates (63 and 25%) compared to the patients without CD9 expression (39 and 11%). Univariate analysis revealed that patients with CD9 expression demonstrated a more favorable survival (P=0.0025) along with other clinicopathological factors, including age younger than 60 years, IMIG stage I-II, epithelioid histology, EM-D and patients who underwent extrapleural pneumonectomy or received chemotherapy. Multivariate analysis identified CD9 expression as an independent prognostic factor with a hazard ratio (HR) of 1.99 in the analysis of all mesotheliomas (P=0.0261) and an HR of 2.60 in the analysis of EMs (P=0.0376). CD9 expression is an independent favorable prognostic marker of malignant mesothelioma.

AB - CD9 is involved in cell growth, adhesion and motility and its expression is reported to be of prognostic significance in various types of human malignancies. We found increased cell migration in the mesothelioma cell lines MSTO-211H and TUM1 following in vitro shRNA-mediated knockdown of CD9 expression. We investigated CD9 expression in 112 malignant pleural mesotheliomas. CD9 expression was observed in 62 of 71 epithelioid, 13 of 20 biphasic and only 1 of 21 sarcomatoid mesotheliomas. Among the epithelioid mesotheliomas (EMs), CD9 expression was observed in all of the 33 cases with a differentiated type (EM-D) and in 29 of the 38 cases with a less-differentiated type (EM-LD). Patients with CD9 expression showed higher 1- and 2-year survival rates (63 and 25%) compared to the patients without CD9 expression (39 and 11%). Univariate analysis revealed that patients with CD9 expression demonstrated a more favorable survival (P=0.0025) along with other clinicopathological factors, including age younger than 60 years, IMIG stage I-II, epithelioid histology, EM-D and patients who underwent extrapleural pneumonectomy or received chemotherapy. Multivariate analysis identified CD9 expression as an independent prognostic factor with a hazard ratio (HR) of 1.99 in the analysis of all mesotheliomas (P=0.0261) and an HR of 2.60 in the analysis of EMs (P=0.0376). CD9 expression is an independent favorable prognostic marker of malignant mesothelioma.

KW - CD9 immunohistochemistry

KW - CD9-shRNA

KW - Mesothelioma

KW - Migration

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84872873243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872873243&partnerID=8YFLogxK

U2 - 10.3892/or.2012.2116

DO - 10.3892/or.2012.2116

M3 - Article

VL - 29

SP - 21

EP - 28

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -